Nasdaq IPOs

TCW Special Purpose Acquisition, a blank check company formed by TCW Group targeting the tech, healthcare, industrial, or consumer sectors, filed on Friday with the SEC to raise up to $400 million in an initial public offering. The Los Angeles, CA-based company plans to raise $4

American Acquisition Opportunity, a blank check company formed by the founders of Land Betterment Corp targeting land and resource holding companies, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The Fishers, IN-based company plans to ra

Every year, hundreds of companies turn to the public markets to raise capital to fund future growth, reward early investors and achieve broader name recognition and deeper awareness of its services and products. But have you ever wondered how a company becomes a listed company?

Property Solutions Acquisition II, the second blank check company formed by Benchmark Real Estate Group targeting the real estate industry, filed on Friday with the SEC to raise up to $250 million in an initial public offering. The New York, NY-based company plans to raise $250

Angion Biomedica, a Phase 3 biotech developing small molecule therapies for acute organ injuries, raised $80 million by offering 5 million shares at $16, the high end of the range of $14 to $16. The company's lead candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic

Evaxion Biotech, a Danish Phase 1/2 biotech using AI to develop immuno-oncology therapies, raised $30 million by offering 3 million ADSs at $10, the low end of the range of $10 to $12. The company offered 0.3 million more ADSs than anticipated. The company is using the AI techno

Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, raised $230 million by offering 11.5 million shares at $20, above the upwardly revised range of $18 to $19. The company offered 1 million more shares than anticipated. It originally planned

Vor Biopharma, a preclinical biotech developing cell therapies for hematological diseases, raised $177 million by offering 9.8 million shares at $18, the high end of the range of $16 to $18. The company offered 1 million more shares than anticipated. At pricing, Vor Biopharma com

Sustainable Development Acquisition I, a blank check public benefit corporation formed by RRG and Capricorn Investment Group, raised $275 million by offering 27.5 million units at $10. The company offered 2.5 million more units than anticipated. Each unit consists of one sha

Ark Global Acquisition, a blank check company led by a former Groupon CEO and QIA fund manager targeting disruptive technology, raised $300 million by offering 30 million units at $10. The company offered 5 million more units than anticipated. Each unit consists of one share of c

Fifth Wall Acquisition I, a blank check company targeting a real estate technology business, raised $300 million by offering 30 million shares at $10. The company did not offer units with warrants attached. The company is led by CEO and Chairman Brendan Wallace, who ha

Thunder Bridge Capital Partners III, the third blank check company led by Gary Simanson targeting the fintech industry, raised $360 million by offering 36 million units at $10. The company offered 6 million more units than anticipated. Each unit consists of one share of comm

Compute Health Acquisition, a blank check company targeting the intersection of computation and healthcare, raised $750 million by offering 75 million units at $10. Each unit consists of one share of common stock and one-fourth of a warrant, exercisable at $11.50. Medical de

G Squared Ascend I, a blank check company formed by G Squared targeting the tech sector, raised $300 million by offering 30 million units at $10.The company offered 5 million more units than anticipated. Each unit consists of one share of common stock and one-fifth of a warrant,

JOFF Fintech Acquisition, a blank check company targeting the financial services industry and FinTech, raised $360 million by offering 36 million units at $10. The company offered 6 million more units than anticipated. Each unit consists of one share of common stock and one-

RMG Acquisition III, the third blank check company formed by Riverside's James Carpenter and former Carlyle executive Robert Mancini, raised $420 million by offering 42 million units at $10. Each unit consists of one share of common stock and one-fifth of a warrant, exercisa

Lucira Health, which is developing single-use test kits for COVID-19 and other infectious diseases, raised $153 million by offering 9 million shares at $17, the high end of the range of $15 to $17. The company previously planned to offer 7.8 million shares. At $17, Lucira command

Pharvaris, a Phase 1 biotech developing oral small molecule therapies for rare diseases, raised $165 million by offering 8.3 million shares at $20, above the range of $17 to $19. The company sold 19% more shares than originally anticipated. The Netherlands-based biotech, which h

Immunocore Holdings, a Phase 3 biotech developing T cell therapies for cancer and other diseases, raised $258 million by offering 9.9 million ADSs at $26, above the range of $23 to $25. The company offered 19% more ADSs than anticipated at $26 based on an F-1MEF filing late Thurs

Immunocore Holdings, a Phase 3 biotech developing T cell therapies for cancer and other diseases, raised $258 million by offering 9.9 million ADSs at $26, above the range of $23 to $25. The company offered 19% more ADSs than anticipated at $26 based on an F-1MEF filing late Thurs